SC
NGNE icon

Steven Cohen’s Neurogene NGNE Stock Holding History

Steven Cohen’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46M Buy
+141,920
New +$3.91M ﹤0.01% 1836
2025
Q4 		– Sell
-7,669
Closed -$133K – 4079
2025
Q3 		$133K Buy
+7,669
New +$154K ﹤0.01% 2185
2024
Q2 		– Sell
-28,033
Closed -$1.43M – 2260
2024
Q1 		$1.43M Buy
+28,033
New +$936K ﹤0.01% 1376
2023
Q4 		– Sell
-6,834
Closed -$108K – 2592
2023
Q3 		$108K Hold
6,834
– – ﹤0.01% 1949
2023
Q2 		$113K Hold
6,834
– – ﹤0.01% 1515
2023
Q1 		$95.7K Hold
6,834
– – ﹤0.01% 1640
2022
Q4 		$69.6K Sell
6,834
-96,377
-93% -$995K ﹤0.01% 1324
2022
Q3 		$1.32M Buy
103,211
+31,340
+44% +$640K 0.01% 1011
2022
Q2 		$1.48M Buy
71,871
+10,621
+17% +$259K 0.01% 1002
2022
Q1 		$2.3M Buy
61,250
+10,710
+21% +$625K 0.01% 855
2021
Q4 		$4.87M Buy
50,540
+540
+1% +$65.8K 0.02% 682
2021
Q3 		$7.23M Buy
50,000
+5,845
+13% +$895K 0.03% 569
2021
Q2 		$8.15M Sell
44,155
-21,275
-33% -$4.71M 0.04% 500
2021
Q1 		$16.1M Buy
65,430
+5,644
+9% +$1.44M 0.08% 314
2020
Q4 		$16.9M Buy
59,786
+9,801
+20% +$2.39M 0.08% 316
2020
Q3 		$12M Buy
49,985
+25,435
+104% +$6.16M 0.06% 374
2020
Q2 		$8.15M Sell
24,550
-5,510
-18% -$1.44M 0.05% 384
2020
Q1 		$6.84M Buy
30,060
+23,721
+374% +$4.88M 0.06% 349
2019
Q4 		$1.56M Buy
+6,339
New +$631K 0.01% 653
2018
Q2 		– Sell
-12,505
Closed -$3.52M – 1117
2018
Q1 		$3.52M Sell
12,505
-3,750
-23% -$1.04M 0.01% 649
2017
Q4 		$3.82M Buy
+16,255
New +$3.81M 0.02% 640

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Steven Cohen's NGNE Position: Q2 2026 in Review

Steven Cohen opened a new position in Neurogene (NGNE) in Q2 2026: 141,920 shares worth $4.46M. The stake represents ﹤0.01% of the portfolio and ranks #1836 among its holdings. This is a return to the name: Steven Cohen previously reported a position in NGNE as recently as Q3 2025.

Steven Cohen first reported a position in NGNE in Q4 2017 and has held it in 21 quarters since. The position peaked at $16.9M in Q4 2020. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Steven Cohen held 141,920 shares of Neurogene worth $4.46M as of Q2 2026.
  • Neurogene was a new Steven Cohen position in Q2 2026.
  • Neurogene made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #1836 holding.
  • Steven Cohen first reported a position in Neurogene in Q4 2017 and has held it in 21 quarters since.
  • Steven Cohen's Neurogene position peaked at $16.9M in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.